TG Therapeutics
A commercial-stage immunotherapy company focused on the development of novel treatments for B-cell malignancies and autoimmune diseases.
About
TG Therapeutics is a commercial-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for patients with B-cell malignancies and autoimmune diseases. The company's pipeline includes a combination of novel small molecules and antibodies designed to target key pathways involved in these diseases. Their lead programs, ublituximab and umbralisib, are being investigated in various hematologic cancers and autoimmune conditions. Teams look it up for Biotechnology, Pharmaceuticals, Healthcare.
Frequently asked
What does TG Therapeutics do?
TG Therapeutics is a Biotechnology company that offers Services. Teams look it up for Pharmaceuticals, Healthcare. It is based in New York, New York, USA and was founded in 2011. Public records show about 497 people and $360M raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has TG Therapeutics raised?
TG Therapeutics has raised a total of $360M in funding. The most recent round on record is Public Stock Offering.
Where is TG Therapeutics headquartered?
TG Therapeutics is headquartered in New York, New York, USA.
When was TG Therapeutics founded?
TG Therapeutics was founded in 2011.
What industry does TG Therapeutics operate in?
TG Therapeutics operates in Biotechnology, Pharmaceuticals, Healthcare.
How many employees does TG Therapeutics have?
TG Therapeutics has approximately 497 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.